These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 32392947)

  • 21. Serum c-erbB-2 protein is a useful marker for monitoring tumor recurrence of the breast.
    Imoto S; Wada N; Hasebe T; Ochiai A; Kitoh T
    Int J Cancer; 2007 Jan; 120(2):357-61. PubMed ID: 17044019
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers.
    Sjögren S; Inganäs M; Lindgren A; Holmberg L; Bergh J
    J Clin Oncol; 1998 Feb; 16(2):462-9. PubMed ID: 9469329
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [HER2 testing in breast cancer].
    Yoshimura K
    Nihon Rinsho; 2007 Jun; 65 Suppl 6():275-80. PubMed ID: 17682167
    [No Abstract]   [Full Text] [Related]  

  • 24. New trends in molecular biomarker discovery for breast cancer.
    Radpour R; Barekati Z; Kohler C; Holzgreve W; Zhong XY
    Genet Test Mol Biomarkers; 2009 Oct; 13(5):565-71. PubMed ID: 19814613
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeted treatments for breast cancer: a step forward.
    Bachelot T; Tredan O
    Lancet Oncol; 2013 May; 14(6):438-9. PubMed ID: 23602602
    [No Abstract]   [Full Text] [Related]  

  • 26. HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial.
    Llombart-Cussac A; Cortés J; Paré L; Galván P; Bermejo B; Martínez N; Vidal M; Pernas S; López R; Muñoz M; Nuciforo P; Morales S; Oliveira M; de la Peña L; Peláez A; Prat A
    Lancet Oncol; 2017 Apr; 18(4):545-554. PubMed ID: 28238593
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A preliminary study of CA15-3, c-erbB-2, epidermal growth factor receptor, cathepsin-D, and p53 in saliva among women with breast carcinoma.
    Streckfus C; Bigler L; Tucci M; Thigpen JT
    Cancer Invest; 2000; 18(2):101-9. PubMed ID: 10705871
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Routine Use of Oncotype DX Recurrence Score Testing in Node-Positive Hormone Receptor-Positive HER2-Negative Breast Cancer: The Time Has Come.
    Mittendorf EA; King TA
    Ann Surg Oncol; 2019 May; 26(5):1173-1175. PubMed ID: 30798446
    [No Abstract]   [Full Text] [Related]  

  • 29. Plasma c-erbB-2 levels in breast cancer patients: prognostic significance in predicting response to chemotherapy.
    Mehta RR; McDermott JH; Hieken TJ; Marler KC; Patel MK; Wild LD; Das Gupta TK
    J Clin Oncol; 1998 Jul; 16(7):2409-16. PubMed ID: 9667258
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mammographic density in relation to tumor biomarkers, molecular subtypes, and mode of detection in breast cancer.
    Sartor H; Zackrisson S; Elebro K; Hartman L; Borgquist S
    Cancer Causes Control; 2015 Jun; 26(6):931-9. PubMed ID: 25860114
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overexpression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancer.
    Noguchi M
    Ann Surg; 1995 Apr; 221(4):433-5. PubMed ID: 7726682
    [No Abstract]   [Full Text] [Related]  

  • 32. Identification of cell-surface markers for detecting breast cancer cells in ovarian tissue.
    Peters IT; Hilders CG; Sier CF; Vahrmeijer AL; Smit VT; Baptist Trimbos J; Kuppen PJ
    Arch Gynecol Obstet; 2016 Aug; 294(2):385-93. PubMed ID: 26946151
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Abnormal expression of four novel molecular markers represents a highly aggressive phenotype in breast cancer. Immunohistochemical assay of p53, nm23, erbB-2, and cathepsin D protein.
    Han S; Yun IJ; Noh DY; Choe KJ; Song SY; Chi JG
    J Surg Oncol; 1997 May; 65(1):22-7. PubMed ID: 9179263
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Updated UK Recommendations for HER2 assessment in breast cancer.
    Rakha EA; Pinder SE; Bartlett JM; Ibrahim M; Starczynski J; Carder PJ; Provenzano E; Hanby A; Hales S; Lee AH; Ellis IO;
    J Clin Pathol; 2015 Feb; 68(2):93-9. PubMed ID: 25488926
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The potential use of saliva to detect recurrence of disease in women with breast carcinoma.
    Bigler LR; Streckfus CF; Copeland L; Burns R; Dai X; Kuhn M; Martin P; Bigler SA
    J Oral Pathol Med; 2002 Aug; 31(7):421-31. PubMed ID: 12165061
    [TBL] [Abstract][Full Text] [Related]  

  • 36. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer.
    Thor AD; Berry DA; Budman DR; Muss HB; Kute T; Henderson IC; Barcos M; Cirrincione C; Edgerton S; Allred C; Norton L; Liu ET
    J Natl Cancer Inst; 1998 Sep; 90(18):1346-60. PubMed ID: 9747866
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Updated 2018 ASCO/CAP recommendations on the definition of human epidermal growth factor receptor type 2 (HER2) in breast cancer].
    Zavalishina LE; Andreeva YY; Olyushina EM; Moskvina LV; Frank GA
    Arkh Patol; 2019; 81(6):82-85. PubMed ID: 31851198
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined measurement of the c-erbB-2 protein in breast carcinoma tissues and sera is useful as a sensitive tumor marker for monitoring tumor relapse.
    Sugano K; Ushiama M; Fukutomi T; Tsuda H; Kitoh T; Ohkura H
    Int J Cancer; 2000 Jul; 89(4):329-36. PubMed ID: 10956406
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ki67 in breast cancer: a useful prognostic marker?
    Caldarella A; Crocetti E; Paci E
    Ann Oncol; 2014 Feb; 25(2):542. PubMed ID: 24412822
    [No Abstract]   [Full Text] [Related]  

  • 40. Prognostic and predictive significance of ErbB-2 breast tumor levels measured by enzyme immunoassay.
    Eppenberger-Castori S; Kueng W; Benz C; Caduff R; Varga Z; Bannwart F; Fink D; Dieterich H; Hohl M; Müller H; Paris K; Schoumacher F; Eppenberger U
    J Clin Oncol; 2001 Feb; 19(3):645-56. PubMed ID: 11157014
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.